#Denmark #Copenhagen #Glioblastoma #Curasight #uTREAT

Curasight's Breakthrough in Glioblastoma Treatment

Curasight A/S, a clinical-stage radiopharmaceutical company, has made significant strides in developing its innovative treatment, uTREAT®, for glioblastoma, an aggressive form of brain cancer. Recently, the company announced the preliminary findings from its Phase 1 clinical trial, which have shown promising outcomes regarding both the safety and feasibility of this novel therapy.

In this trial, patients suffering from glioblastoma received uTREAT® through a technique known as super-selective intra-arterial cerebral injection (super-SIACI). This method allows for a precise delivery of the treatment by injecting it directly into the blood vessels that supply the tumor. Moreover, to enhance the targeting of the drug, a temporary opening of the blood-brain barrier was achieved using mannitol, an osmotic compound.

The preliminary readout indicates several key findings:
1. Feasibility and Safety: The application method demonstrated that uTREAT® could be safely administered without exceeding the radiation dose limits for healthy organs. This is particularly important, as glioblastoma treatments often come with high risks of collateral damage to surrounding healthy tissues.
2. High Tumor Uptake: Results illustrated substantial uptake and retention of the treatment within the tumor, suggesting that uTREAT® effectively targets the cancer cells. The biodistribution and dosimetry were compatible with delivering a therapeutic dose directly to the tumors, potentially making it more effective compared to traditional therapies.
3. Future Development: Based on these encouraging results, Curasight's CEO, Ulrich Krasilnikoff, expressed confidence in moving forward with the trial. He emphasized the aim to develop uTREAT® as a potentially groundbreaking radioligand therapy that could change the treatment landscape for glioblastoma patients.

About the Phase 1 Trial

The main objective of this Phase 1 trial is to evaluate the safety and efficacy of uTREAT® as a targeted radioligand therapy for patients diagnosed with newly identified glioblastoma. With approximately 65,000 individuals diagnosed with primary brain tumors annually in the U.S. and EU, and over 30,000 of these cases being glioblastoma, there is a pressing need for innovative therapies that offer better outcomes for patients.

Currently, the prognosis for glioblastoma patients is grim, with roughly 50% succumbing to the disease within 14 months of diagnosis. Traditional external beam radiation poses the challenge of exposing healthy tissue to high doses of radiation, which could potentially be mitigated with localized approaches like uTREAT®.

Curasight's uPAR Theranostic Platform

In addition to uTREAT®, Curasight has developed the uPAR theranostic platform, which incorporates another technology, uTRACE®. Together, these two approaches enable sensitive imaging for diagnosis and targeted treatment for cancers that express uPAR. The integration of uTRACE® and uTREAT® underscores Curasight's commitment to enhancing cancer diagnosis and treatment through cutting-edge technologies.

As Curasight continues to collect and analyze data from this trial, its integrated approach may pave the way for more effective treatments for patients battling glioblastoma and high-grade gliomas, ultimately improving survival rates and quality of life. The journey of uTREAT®, from clinical trials to potential widespread use, exemplifies the ongoing efforts to combat one of the most challenging forms of cancer today.